¼¼°è ½É±ÙÁõ Ä¡·á ½ÃÀå
Cardiomyopathy Therapies
»óǰÄÚµå : 1534092
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,015,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,045,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½É±Ùº´ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 34¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»ó

2023³â¿¡ 30¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ½É±ÙÁõ Ä¡·á ¼¼°è ½ÃÀåÀº 2023-2030³â ºÐ¼® ±â°£¿¡ CAGR 1.7%·Î ¼ºÀåÇϰí 2030³â¿¡´Â 34¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ È®ÀåÇü ½É±ÙÁõÀº CAGR 1.9%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 19¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ´ëÇü ½É±ÙÁõ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 1.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 2,200¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 3.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ ½É±ÙÁõ Ä¡·á ½ÃÀåÀº 2023³â 8¾ï 2,200¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023-2030³â°£ CAGR 3.0%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 6¾ï 2,500¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 0.8%¿Í 1.5%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ½É±ÙÁõ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ ¿ä¾à

½É±ÙÁõÀº Ç÷¾×À» È¿°úÀûÀ¸·Î Àü´ÞÇÏ´Â ½ÉÀåÀÇ ÆßÇÁ ±â´ÉÀ» ¼Õ»ó½ÃŰ´Â º¹ÀâÇϰí ÀÌÁúÀûÀÎ ½É±Ù Áúȯ ±×·ìÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº È®ÀåÇü, ºñ´ëÇü, ±¸¼ÓÇü, ºÎÁ¤¸Æ¿ø¼º ¿ì½É½Ç±Ù°ú °°Àº ¿©·¯ À¯ÇüÀ¸·Î ºÐ·ùµË´Ï´Ù. °¢ À¯Çü¿¡´Â °¢°¢ ´Ù¸¥ º´ÀÎ, º´ÅÂ, ÀÓ»ó»óÀÌ ÀÖÀ¸¸ç, °¢°¢¿¡ ¸Â´Â Ä¡·á ¹æ¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù. ½É±ÙÁõ¿¡ ´ëÇÑ ÇöÀçÀÇ Ä¡·á ¿É¼ÇÀº º£Å¸ Â÷´ÜÁ¦, ACE ¾ïÁ¦Á¦, Ç×ÀÀ°íÁ¦ µîÀÇ ¾à¸®ÇÐÀû °³ÀÔÀ¸·Î ÀÎÇÑ »ýȰ ½À°ü °³¼±, ½É¹Ú Á¶À²±â ¹× Á¦¼¼µ¿±â¿Í °°Àº ÀÌ½Ä °¡´ÉÇÑ ÀåÄ¡ÀÇ »ç¿ë°ú °°Àº ºñ¾à ¹°¸®Àû Àü·«±îÁö ´Ù¾çÇÕ´Ï´Ù. ½ÉÇÑ °æ¿ì¿¡´Â ½ÉÀå Àç µ¿±âÈ­ Ä¡·á, º¸Á¶ Àΰø ½ÉÀå ¶Ç´Â ½ÉÀå À̽İú °°Àº °í±Þ Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. ´Ù¾çÇÑ Ä¡·á¹ýÀÌ ÀÖÀ½¿¡µµ ºÒ±¸ÇÏ°í ½É±ÙÁõÀº ÁøÇ༺ÀÌ°í ½ÉÀå µ¹¿¬»çÀÇ °¡´É¼ºÀÌ Àֱ⠶§¹®¿¡ °ü¸®´Â ¿©ÀüÈ÷ ¾î·Æ½À´Ï´Ù.

ÃÖ±Ù ½É±ÙÁõÀÇ ºÐÀÚÀû¡¤À¯ÀüÀû ±â¹ÝÀÇ ÇØ¸íÀÌ ÁøÇàµÇ¾î Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ±æÀÌ ¿­·È½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á¿Í ºÐÀÚ Ç¥Àû Ä¡·á´Â ¿¬±¸ÀÇ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç ƯÁ¤ À¯Àü ÇüÅÂÀÇ ½É±ÙÁõ¿¡ ´ëÇÑ Ä¡À¯ ¼Ö·ç¼ÇÀÇ ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, CRISPR-Cas9 À¯ÀüÀÚ ÆíÁý°ú RNA °£¼·Àº ½É±ÙÁõÀ» ÀÏÀ¸Å°´Â °áÇÔ À¯ÀüÀÚ¸¦ ¼öÁ¤Çϰųª ħ¹¬½Ã۱â À§ÇØ ¿¬±¸µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¹Ì¿À½Å ¾ïÁ¦Á¦ ¹× ¼±ÅÃÀû ½É±Ù ¹Ì¿À½Å Ȱ¼ºÈ­Á¦¿Í °°Àº »õ·Î¿î ¾à¸®ÇÐÀû ¾à¹°ÀÇ °³¹ßÀº ½ÉÀå ¼öÃà·ÂÀ» Á÷Á¢ Á¶ÀýÇÏ°í ½ÉÀå ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. Áٱ⼼Æ÷ Ä¡·áµµ À¯¸ÁÇϸç, ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè¿¡¼­´Â ¼Õ»óµÈ ½ÉÀåÁ¶Á÷À» Àç»ýÇÏ°í ½É±Ù±â´ÉÀ» ȸº¹½Ãų °¡´É¼ºÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃÖ÷´Ü Ä¡·á¹ýÀº Â÷¼¼´ë ½ÃÄö½Ì ¹× °í±Þ À̹Ì¡ ±â¼úÀ» Æ÷ÇÔÇÑ Áø´Ü µµ±¸ÀÇ Áøº¸·Î º¸¿ÏµÇ¾î Á¶±â ¹× Á¤È®ÇÑ Áø´ÜÀ» ¿ëÀÌÇÏ°Ô ÇÏ¿© Àû½Ã¿¡ ÀûÁ¤ÇÑ °³ÀÔÀÌ °¡´É µË´Ï´Ù.

½É±ÙÁõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ ³ëÈ­·Î ÀÎÇØ È¿°úÀûÀÎ ½É±Ùº´ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áø´Ü ¹× Ä¡·á ¹æ¹ýÀÇ ±â¼úÀû Áøº¸´Â À̿밡´ÉÇÑ Ä¡·á ¿É¼ÇÀÇ ÆøÀ» ³ÐÇô ´õ¿í °³º°È­µÈ È¿°úÀûÀÎ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù. ȯÀÚ¿Í ÀÇ·á Á¾»çÀÚÀÇ ½É±Ù º´Áõ¿¡ ´ëÇÑ Àνİú ÀÌÇØÀÇ Çâ»óÀº Á¶±â Áø´Ü°ú Á¶±â °³ÀÔÀ¸·Î À̾îÁ® ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ Á¦¾àȸ»ç³ª Çмú±â°ü¿¡ ÀÇÇÑ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ ÇÔÀ¸·Î½á »õ·Î¿î Ä¡·á¹ýÀÇ ¹ß°ß°ú »ó¾÷È­°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº Áö¿ªÀÇ Á¤ºÎ Áö¿ø Á¤Ã¥°ú À¯¸®ÇÑ »óȯÀÇ Æ²Àº ´õ ¸¹Àº ȯÀÚµéÀÌ Ã·´Ü Ä¡·á¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï Çϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ¿ø°Ý ÀÇ·á¿Í °°Àº µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕÀº ȯÀÚ °ü¸® ¹× Ä¡·á¿¡ ´ëÇÑ ¾îµåÈ÷¾î·±½º¸¦ °­È­ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ½É±ÙÁõ Ä¡·á ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(Àü 86°Ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cardiomyopathy Therapies Market to Reach US$3.4 Billion by 2030

The global market for Cardiomyopathy Therapies estimated at US$3.0 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Dilated Cardiomyopathy, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Hypertrophic Cardiomyopathy segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.0 Million While China is Forecast to Grow at 3.0% CAGR

The Cardiomyopathy Therapies market in the U.S. is estimated at US$822.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Cardiomyopathy Therapies Market - Key Trends and Drivers Summarized

Cardiomyopathy is a complex and heterogeneous group of heart muscle diseases that impair the heart's ability to pump blood effectively. These conditions can be classified into several types, including dilated, hypertrophic, restrictive, and arrhythmogenic right ventricular cardiomyopathy. Each type has distinct etiologies, pathophysiologies, and clinical presentations, necessitating tailored therapeutic approaches. Current treatment options for cardiomyopathy range from pharmacological interventions such as beta-blockers, ACE inhibitors, and anticoagulants, to non-pharmacological strategies, including lifestyle modifications and the use of implantable devices like pacemakers and defibrillators. In severe cases, patients may require advanced therapies such as cardiac resynchronization therapy, ventricular assist devices, or even heart transplantation. Despite the variety of treatments available, managing cardiomyopathy remains challenging due to its progressive nature and the potential for sudden cardiac death.

Recent advancements in the understanding of molecular and genetic underpinnings of cardiomyopathy have paved the way for innovative therapeutic approaches. Gene therapy and molecular-targeted therapies are at the forefront of research, offering potential curative solutions for certain genetic forms of cardiomyopathy. For instance, CRISPR-Cas9 gene editing and RNA interference are being explored to correct or silence defective genes responsible for cardiomyopathy. Additionally, the development of novel pharmacological agents, such as myosin inhibitors and selective cardiac myosin activators, is aimed at directly modulating cardiac contractility and improving heart function. Stem cell therapy also holds promise, with ongoing clinical trials investigating its potential to regenerate damaged heart tissue and restore myocardial function. These cutting-edge therapies are complemented by advancements in diagnostic tools, including next-generation sequencing and advanced imaging techniques, which facilitate early and precise diagnosis, thereby enabling timely and targeted interventions.

The growth in the cardiomyopathy therapies market is driven by several factors. The rising prevalence of cardiovascular diseases, particularly in aging populations, has significantly increased the demand for effective cardiomyopathy treatments. Technological advancements in diagnostic and therapeutic modalities have expanded the range of available treatment options, making it possible to offer more personalized and effective care. Increased awareness and understanding of cardiomyopathy among patients and healthcare providers have led to earlier diagnosis and intervention, improving patient outcomes. Furthermore, substantial investments in research and development by pharmaceutical companies and academic institutions are accelerating the discovery and commercialization of novel therapies. Supportive government policies and favorable reimbursement frameworks in many regions are also playing a crucial role in making advanced treatments accessible to a broader patient population. Additionally, the integration of digital health technologies, such as remote monitoring and telemedicine, is enhancing patient management and adherence to therapy, thereby driving market growth. Collectively, these factors are fostering a dynamic and rapidly evolving market for cardiomyopathy therapies.

Select Competitors (Total 86 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â